On April 1, 2026 Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics to improve the safety and efficacy of cancer therapies, reported upcoming oral presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 and the Antibody Engineering & Therapeutics (AET) Europe conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Voro Therapeutics will present new preclinical data showcasing the power of its proprietary PrimeBody biologics platform and the broad therapeutic index of its lead program, VOR-101. The presentations will demonstrate how PrimeBody’s novel protease-cleavable linkers and affinity-tuned masking domains drive tumor-selective activation, enabling the safe and effective deployment of highly potent warheads that are not achievable with conventional approaches. Voro will also highlight the platform’s broader potential through applications in T-cell engagers, antibody-drug conjugates and cytokines.
Presentation Details
American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026
San Diego Convention Center • San Diego, CA • April 17–22, 2026
Date: April 20th, 2026
Session: MS.IM01.02 – Advances in Therapeutic Antibodies
Title: Tumor-Activated PrimeBody Biologics Platform Enables More Potent CD47 Targeting and Superior Therapeutic Index in Preclinical Models
Presenter: Aaron Springer, PhD, Associate Director of Preclinical Biology, Voro Therapeutics
Conference Link: View Source
Antibody Engineering & Therapeutics (AET) Europe
Congress Center Basel • Basel, Switzerland • May 27–29, 2026
Date: May 29th, 2026
Session: Masked, Gated, Conditionally Activated Antibodies
Title: Tumor-Activated PrimeBody Platform Unlocks the Safe and Effective Delivery of Potent Biologics Beyond the Reach of Conventional Approaches
Presenter: Ugur Eskiocak, PhD, Co-Founder and CEO, Voro Therapeutics
Conference Link: https://informaconnect.com/antibody-engineering-europe/
(Press release, Voro Therapeutics, APR 1, 2026, View Source [SID1234664129])